Caroline Theresa Seebauer1, Berit Hackenberg2, Jirka Grosse3, Janine Rennert4, Ernst-Michael Jung4, Ines Ugele1, Ioannis Michaelides1, Hisham Mehanna5, Matthias G Hautmann6, Christopher Bohr1, Julian Künzel7. 1. Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital of Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany. 2. Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Center of Mainz, 55131, Mainz, Germany. 3. Department of Nuclear Medicine, University Hospital of Regensburg, 93053, Regensburg, Germany. 4. Institute of Radiology, University Hospital of Regensburg, 93053, Regensburg, Germany. 5. Department of Head and Neck Surgery, University of Birmingham, B15 2TT, Birmingham, UK. 6. Department of Radiotherapy, University Hospital of Regensburg, 93053, Regensburg, Germany. 7. Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital of Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany. julian.kuenzel@ukr.de.
Abstract
PURPOSE: Treatment of patients with laryngeal squamous cell carcinoma with radiotherapy or chemoradiation is an established alternative to laryngeal surgery in many cases, but particularly for advanced tumors without cartilage invasion. Imaging modalities face the challenge of distinguishing between posttherapeutic changes and residual disease in the complex anatomic subsite of the larynx. Guidelines concerning restaging of head and neck squamous cell carcinomas (HNSCC) are presented by the National Comprehensive Cancer Network (NCCN) and other national guidelines, but clearly defined recommendations for routine restaging particularly for laryngeal cancer are lacking. METHODS: A systematic search was carried out in PubMed to identify studies evaluating routine restaging methods after primary non-surgical treatment of laryngeal squamous cell carcinoma from 2009 to 2020. RESULTS: Only three studies were deemed eligible, as they included at least ≥50% patients with laryngeal squamous cell carcinoma and evaluated imaging modalities to detect residual cancer. The small number of studies in our review suggest restaging with fluoro-deoxy-glucose positron-emission tomography/computed tomography (FDG PET/CT) 3 months after initial treatment, followed by direct laryngoscopy with biopsy of the lesions identified by FDG PET/CT. CONCLUSION: Studies evaluating restaging methods after organ-preserving non-surgical treatment of laryngeal carcinoma are limited. As radiotherapy (RT), chemoradiotherapy (CRT), systemic therapy followed by RT and radioimmunotherapy are established alternatives to surgical treatment, particularly in advanced laryngeal cancers, further studies are needed to assess and compare different imaging modalities (e.g. PET/CT, MRI, CT, ultrasound) and clinical diagnostic tools (e.g., video laryngoscopy, direct laryngoscopy) to offer patients safe and efficient restaging strategies. PET or PET/CT 3 months after initial treatment followed by direct laryngoscopy with biopsy of the identified lesions has the potential to reduce the number of unnecessary laryngoscopies.
PURPOSE: Treatment of patients with laryngeal squamous cell carcinoma with radiotherapy or chemoradiation is an established alternative to laryngeal surgery in many cases, but particularly for advanced tumors without cartilage invasion. Imaging modalities face the challenge of distinguishing between posttherapeutic changes and residual disease in the complex anatomic subsite of the larynx. Guidelines concerning restaging of head and neck squamous cell carcinomas (HNSCC) are presented by the National Comprehensive Cancer Network (NCCN) and other national guidelines, but clearly defined recommendations for routine restaging particularly for laryngeal cancer are lacking. METHODS: A systematic search was carried out in PubMed to identify studies evaluating routine restaging methods after primary non-surgical treatment of laryngeal squamous cell carcinoma from 2009 to 2020. RESULTS: Only three studies were deemed eligible, as they included at least ≥50% patients with laryngeal squamous cell carcinoma and evaluated imaging modalities to detect residual cancer. The small number of studies in our review suggest restaging with fluoro-deoxy-glucose positron-emission tomography/computed tomography (FDG PET/CT) 3 months after initial treatment, followed by direct laryngoscopy with biopsy of the lesions identified by FDG PET/CT. CONCLUSION: Studies evaluating restaging methods after organ-preserving non-surgical treatment of laryngeal carcinoma are limited. As radiotherapy (RT), chemoradiotherapy (CRT), systemic therapy followed by RT and radioimmunotherapy are established alternatives to surgical treatment, particularly in advanced laryngeal cancers, further studies are needed to assess and compare different imaging modalities (e.g. PET/CT, MRI, CT, ultrasound) and clinical diagnostic tools (e.g., video laryngoscopy, direct laryngoscopy) to offer patients safe and efficient restaging strategies. PET or PET/CT 3 months after initial treatment followed by direct laryngoscopy with biopsy of the identified lesions has the potential to reduce the number of unnecessary laryngoscopies.
Entities:
Keywords:
Chemoradiotherapy; Imaging; Larynx cancer; Organ-preserving treatment; Radiotherapy; Therapy control
Authors: Hisham Mehanna; Chris C McConkey; Joy K Rahman; Wai-Lup Wong; Alison F Smith; Chris Nutting; Andrew Gj Hartley; Peter Hall; Claire Hulme; Dharmesh K Patel; Sandra Ventorin von Zeidler; Max Robinson; Bal Sanghera; Lydia Fresco; Janet A Dunn Journal: Health Technol Assess Date: 2017-04 Impact factor: 4.014
Authors: Jolijn Brouwer; Lotty Hooft; Otto S Hoekstra; Ingrid I Riphagen; Jonas A Castelijns; Remco de Bree; C René Leemans Journal: Head Neck Date: 2008-07 Impact factor: 3.147
Authors: Janine Rennert; Isabel Wiesinger; Lukas Philipp Beyer; Andreas Schicho; Christian Stroszczynski; Philipp Wiggermann; Ernst Michael Jung Journal: Clin Hemorheol Microcirc Date: 2019 Impact factor: 2.375
Authors: C Nelissen; J Sherriff; T Jones; P Guest; S Colley; P Sanghera; A Hartley Journal: Clin Oncol (R Coll Radiol) Date: 2017-08-02 Impact factor: 4.126
Authors: Elvio De Fiori; Giorgio Conte; Mohssen Ansarin; Luigi De Benedetto; Luke Bonello; Daniela Alterio; Fausto Maffini; Massimo Bellomi; Lorenzo Preda Journal: Eur J Radiol Date: 2015-10-30 Impact factor: 3.528
Authors: Lukas B Been; Harald J Hoekstra; Albert J H Suurmeijer; Pieter L Jager; Bernard F A M van der Laan; Philip H Elsinga Journal: Oral Oncol Date: 2009-08-18 Impact factor: 5.337
Authors: A F Smith; P S Hall; C T Hulme; J A Dunn; C C McConkey; J K Rahman; C McCabe; H Mehanna Journal: Eur J Cancer Date: 2017-09-04 Impact factor: 9.162
Authors: Hisham Mehanna; Wai-Lup Wong; Christopher C McConkey; Joy K Rahman; Max Robinson; Andrew G J Hartley; Christopher Nutting; Ned Powell; Hoda Al-Booz; Martin Robinson; Elizabeth Junor; Mohammed Rizwanullah; Sandra V von Zeidler; Hulya Wieshmann; Claire Hulme; Alison F Smith; Peter Hall; Janet Dunn Journal: N Engl J Med Date: 2016-03-23 Impact factor: 91.245
Authors: Antoniu-Oreste Gostian; Rainer Fietkau; Markus Hecht; Markus Eckstein; Sandra Rutzner; Jens von der Grün; Thomas Illmer; Gunther Klautke; Simon Laban; Matthias G Hautmann; Thomas B Brunner; Bálint Tamaskovics; Axel Hinke; Jian-Guo Zhou; Benjamin Frey; Anna-Jasmina Donaubauer; Ina Becker; Sabine Semrau; Arndt Hartmann; Panagiotis Balermpas; Wilfried Budach; Udo S Gaipl; Heinrich Iro Journal: J Immunother Cancer Date: 2022-01 Impact factor: 13.751
Authors: Johannes Doescher; Adrian von Witzleben; Konstantinos Boukas; Stephanie E Weissinger; Gareth J Thomas; Simon Laban; Jaya Thomas; Thomas K Hoffmann; Christian H Ottensmeier Journal: Front Oncol Date: 2022-04-01 Impact factor: 5.738
Authors: Cesare Piazza; Alberto Paderno; Elisabeth V Sjogren; Patrick J Bradley; Hans E Eckel; Antti Mäkitie; Nayla Matar; Vinidh Paleri; Giorgio Peretti; Roberto Puxeddu; Miquel Quer; Marc Remacle; Vincent Vander Poorten; Isabel Vilaseca; Ricard Simo Journal: Eur Arch Otorhinolaryngol Date: 2021-07-05 Impact factor: 2.503